{"log_id": 8444480336574438308, "direction": 0, "words_result_num": 36, "words_result": [{"probability": {"variance": 0, "average": 0.978811, "min": 0.978811}, "location": {"width": 25, "top": 168, "height": 24, "left": 1152}, "words": "品"}, {"probability": {"variance": 8.5e-05, "average": 0.995927, "min": 0.946876}, "location": {"width": 787, "top": 250, "height": 37, "left": 226}, "words": "的辛伐他汀给药剂量时,应考虑到开始托珠单抗治疗后(因CYP3A4水平恢复正常)可能"}, {"probability": {"variance": 6e-06, "average": 0.998779, "min": 0.98658}, "location": {"width": 598, "top": 292, "height": 34, "left": 226}, "words": "降低辛伐他汀的暴露或终止托珠单抗治疗后可能增加辛伐他汀的暴露"}, {"probability": {"variance": 0.011683, "average": 0.934779, "min": 0.747622}, "location": {"width": 84, "top": 338, "height": 25, "left": 269}, "words": "奧美拉唑"}, {"probability": {"variance": 0.000239, "average": 0.992349, "min": 0.907427}, "location": {"width": 746, "top": 370, "height": 35, "left": 268}, "words": "奥美拉唑是CYP2C19和CYP3A4的底物。RA患者接受奥美拉唑10mg,其奥美拉"}, {"probability": {"variance": 0.00204, "average": 0.982758, "min": 0.800139}, "location": {"width": 788, "top": 409, "height": 36, "left": 229}, "words": "唑的暴露比健康受试者高约2倍。RA患者在开始托珠单抗(8mg/kg)输注前和输注后1"}, {"probability": {"variance": 3.4e-05, "average": 0.996161, "min": 0.977099}, "location": {"width": 797, "top": 448, "height": 37, "left": 229}, "words": "周接受奥美拉唑10mg,奥美拉唑 Aucinf(从0至无穷大的血清药物浓度时间曲线下面积)"}, {"probability": {"variance": 4.3e-05, "average": 0.99633, "min": 0.967817}, "location": {"width": 783, "top": 487, "height": 36, "left": 231}, "words": "弱代谢者(N=5)和中等代谢者(N=5)下降12%,强代谢者(N=8)下降28%,略高于"}, {"probability": {"variance": 0, "average": 0.999753, "min": 0.999287}, "location": {"width": 104, "top": 536, "height": 24, "left": 230}, "words": "健康受试者"}, {"probability": {"variance": 1e-06, "average": 0.99894, "min": 0.997433}, "location": {"width": 83, "top": 573, "height": 26, "left": 271}, "words": "右美沙芬"}, {"probability": {"variance": 0.00031, "average": 0.991055, "min": 0.902189}, "location": {"width": 745, "top": 604, "height": 36, "left": 272}, "words": "右美沙芬是CYP2D6和CYP3A4底物。13例RA患者接受右美沙芬30mg,其右美"}, {"probability": {"variance": 0.001001, "average": 0.988701, "min": 0.810234}, "location": {"width": 798, "top": 643, "height": 36, "left": 232}, "words": "沙芬的暴露与健康受试者相似。但其代谢物去甲右美沙芬( dextrorphan)(CYP3A4底物)"}, {"probability": {"variance": 4.1e-05, "average": 0.996689, "min": 0.96893}, "location": {"width": 786, "top": 682, "height": 37, "left": 232}, "words": "的暴露远低于健康受试者。单次输注托珠单抗(8mg/kg)后1周,右美沙芬暴露下降了约"}, {"probability": {"variance": 9e-06, "average": 0.997801, "min": 0.988206}, "location": {"width": 526, "top": 725, "height": 34, "left": 235}, "words": "5%。但托珠单抗输注后,去甲右美沙芬水平下降较大(29%"}, {"probability": {"variance": 1e-06, "average": 0.998747, "min": 0.997111}, "location": {"width": 113, "top": 769, "height": 27, "left": 238}, "words": "【药物过量】"}, {"probability": {"variance": 0.000196, "average": 0.993768, "min": 0.925917}, "location": {"width": 740, "top": 800, "height": 35, "left": 274}, "words": "有关托珠单抗药物过量的资料有限。1位患有多发性骨髓瘤并接受托珠单抗40mg/kg"}, {"probability": {"variance": 2.7e-05, "average": 0.998009, "min": 0.971815}, "location": {"width": 786, "top": 839, "height": 37, "left": 235}, "words": "治疗的患者报告了1例意外的药物过量。没有药物不良反应发生。健康志愿者单次给药最"}, {"probability": {"variance": 1.5e-05, "average": 0.997584, "min": 0.983567}, "location": {"width": 788, "top": 877, "height": 41, "left": 235}, "words": "高至28mg/kg未发生严重药物不良反应,尽管在28mgkg最高剂量组中的全部5例患者"}, {"probability": {"variance": 4.5e-05, "average": 0.996499, "min": 0.977189}, "location": {"width": 343, "top": 922, "height": 33, "left": 236}, "words": "都发生了剂量限制性中性粒细胞减少症"}, {"probability": {"variance": 1.7e-05, "average": 0.997548, "min": 0.976439}, "location": {"width": 746, "top": 956, "height": 38, "left": 276}, "words": "如发生药物过量,建议对患者发生的不良反应症状和体征进行监测。并对发生不良反"}, {"probability": {"variance": 7e-06, "average": 0.997603, "min": 0.991296}, "location": {"width": 201, "top": 1004, "height": 26, "left": 238}, "words": "应的患者进行对症治疗"}, {"probability": {"variance": 4e-06, "average": 0.998098, "min": 0.99551}, "location": {"width": 113, "top": 1046, "height": 25, "left": 245}, "words": "【临床试验】"}, {"probability": {"variance": 0.000224, "average": 0.996442, "min": 0.908058}, "location": {"width": 742, "top": 1074, "height": 38, "left": 284}, "words": "5个随机、双盲、全球多中心的研究评价了托珠单抗改善类风湿关节炎患者症状和体"}, {"probability": {"variance": 0.00456, "average": 0.981259, "min": 0.68169}, "location": {"width": 787, "top": 1114, "height": 37, "left": 240}, "words": "征的有效性。研究I~V均要求患者的年龄≥18岁,根据美国风湿病学会(ACR)标准诊断"}, {"probability": {"variance": 0.000353, "average": 0.994521, "min": 0.894523}, "location": {"width": 620, "top": 1154, "height": 37, "left": 240}, "words": "的活动性类风湿关节炎,并在基线时至少有8个压痛关节,6个肿胀关节"}, {"probability": {"variance": 0.016824, "average": 0.954971, "min": 0.354288}, "location": {"width": 744, "top": 1192, "height": 36, "left": 282}, "words": "研究I是单独应用托珠单抗每4周一次静脉注射,研究Ⅱ,I,V是联用MTX,研究"}, {"probability": {"variance": 0.000556, "average": 0.982628, "min": 0.928742}, "location": {"width": 206, "top": 1241, "height": 24, "left": 244}, "words": "V是联用其它 DMARDS"}, {"probability": {"variance": 0.000276, "average": 0.993275, "min": 0.910837}, "location": {"width": 747, "top": 1269, "height": 40, "left": 282}, "words": "研究I对673名患者进行了评估,这些患者在随机分组前6个月未接受MTX治疗,并且"}, {"probability": {"variance": 4.3e-05, "average": 0.996793, "min": 0.969479}, "location": {"width": 786, "top": 1309, "height": 39, "left": 243}, "words": "未由于重要的临床不良反应或治疗反应不佳而停止既往的MTX治疗。其中大部分患者"}, {"probability": {"variance": 0.001989, "average": 0.988768, "min": 0.70314}, "location": {"width": 754, "top": 1348, "height": 39, "left": 252}, "words": "(67%)从未接受过MTX治疗。托珠单抗组单独给予8mg/kg的托珠单抗每4周一次治疗"}, {"probability": {"variance": 0.003837, "average": 0.978464, "min": 0.617587}, "location": {"width": 785, "top": 1388, "height": 37, "left": 245}, "words": "对照组每周给予MTX(剂量从7.5mg/周开始在8周内逐渐加量至最大剂量20mg/周)。主"}, {"probability": {"variance": 0.000484, "average": 0.992494, "min": 0.883609}, "location": {"width": 513, "top": 1431, "height": 31, "left": 246}, "words": "要终点是在治疗的第24周时达到ACR20的患者百分比。"}, {"probability": {"variance": 6.4e-05, "average": 0.996149, "min": 0.954308}, "location": {"width": 743, "top": 1465, "height": 39, "left": 288}, "words": "研究Ⅱ是一项为期2年的研究,分别在24周和52周时进行了中期评估,研究对象为"}, {"probability": {"variance": 0.048599, "average": 0.767687, "min": 0.38556}, "location": {"width": 931, "top": 1476, "height": 120, "left": 246}, "words": "19MX床佳的C用一ng的珠单抗或股份香港有A"}, {"probability": {"variance": 0.016508, "average": 0.950321, "min": 0.411658}, "location": {"width": 787, "top": 1542, "height": 43, "left": 247}, "words": "盲法治疗52周,同时联用稳定剂量的MTX(10~25mg/周)。主要终点是在治疗第24周"}, {"probability": {"variance": 0, "average": 0.959711, "min": 0.959711}, "location": {"width": 64, "top": 1554, "height": 67, "left": 1032}, "words": "★"}], "language": 3}